FREE SHIPPING
in Germany on orders over €80 ·
Delivery 4-7 Days
International orders: flat rate €17
×
View Cart
Your shopping cart is empty!
Search
Dapocare 60 mg is referred to as a medicinal product containing the active substance dapoxetine. Dapoxetine belongs to the group of selective serotonin reuptake inhibitors (SSRIs) and influences the neurological processes involved in the control of ejaculation. In authorised medicinal products, this active substance is used for the treatment of premature ejaculation (ejaculatio praecox) in adult men.
Important note: In authorised dapoxetine preparations, 60 mg corresponds to the highest recommended single dose and is not intended as a starting dose. Dapoxetine can cause, among other things, dizziness, drops in blood pressure and fainting spells. Particular risks exist with the concurrent use of certain antidepressants and other medicinal products. Alcohol can intensify undesirable effects. Independent use without medical consultation should be avoided.
Dapoxetine is also known as the active substance of the authorised medicinal product Priligy and is subject to prescription in Germany. The correspondence of the stated active substance and its strength does not, however, automatically mean pharmaceutical equivalence. The quality, bioequivalence and marketing authorisation status of Dapocare 60 mg have not been confirmed.
Dapocare 60 mg is the name of a medication with dapoxetine as its stated active ingredient. Dapoxetine belongs to a group of medications known as selective serotonin reuptake inhibitors (SSRIs) and affects signalling pathways in the nervous system involved in the regulation of ejaculation.
According to the blister packaging label, each film-coated tablet contains dapoxetine hydrochloride equivalent to 60 mg of dapoxetine.
The actual active ingredient composition, pharmaceutical quality and compliance with the stated product characteristics must be verified through official manufacturer documentation.
Premature ejaculation, medically referred to as ejaculatio praecox, is a sexual dysfunction in which ejaculation repeatedly occurs earlier than desired and can only be controlled to a limited extent.
Dapoxetine is used in approved medications to treat diagnosed premature ejaculation in men aged 18 to 64 years. The individual underlying causes of the symptoms should be medically assessed before treatment.
Dapoxetine and sildenafil belong to different classes of medications and are used for different medical indications.
Dapoxetine is not a medication for the treatment of erectile dysfunction. Combining it with PDE-5 inhibitors without medical supervision should be avoided due to potential circulatory risks.
According to their product labelling, Dapocare 60 mg and Priligy 60 mg contain the same active ingredient at the same strength. However, this does not establish confirmed pharmaceutical equivalence or bioequivalence.
Dapoxetine is a prescription-only medication in Germany. For approved dapoxetine medications, 60 mg represents the maximum recommended single dose and is not intended as a starting dose.
The regulatory approval status of Dapocare 60 mg in Germany has not been confirmed. The prescribing information for approved dapoxetine medications does not replace a product-specific patient information leaflet for Dapocare.
According to its labelling, Dapocare 60 mg contains the active ingredient dapoxetine. Due to the stated strength and potential side effects, medical assessment before use is particularly important.
Before starting treatment with dapoxetine, the underlying causes of premature ejaculation and the individual's general health status should be assessed. This includes, in particular, an evaluation of cardiovascular function and blood pressure regulation.
Particular attention should be paid to the following health conditions:
For approved dapoxetine medications, 60 mg represents the maximum recommended single dose. This strength is not intended as a starting dose and may be associated with an increased risk of adverse effects.
No confirmed product-specific prescribing information is available for Dapocare 60 mg. Therefore, dosage recommendations for other dapoxetine-containing medications cannot be directly applied to Dapocare.
Combining dapoxetine with alcohol may increase dizziness, drowsiness and circulatory problems. It may also increase the risk of fainting and associated injuries.
Dehydration may also contribute to circulatory problems, particularly when fluid loss is increased due to fever, diarrhoea or excessive sweating.
Dapoxetine may interact with various medications. Particular risks are associated with certain antidepressants, serotonergic substances and medications that affect the metabolism of dapoxetine.
The prescribing information for Priligy also advises against concurrent use with PDE-5 inhibitors such as sildenafil or tadalafil, as this may impair cardiovascular regulation.
Immediate medical attention is required if any of the following symptoms occur:
Use of Dapocare 60 mg without prior medical assessment should be avoided. The medical suitability of treatment must be assessed individually.
Dapoxetine, the active ingredient listed for Dapocare 60 mg, may cause adverse effects on the nervous system, digestive tract and cardiovascular system. The risk of certain side effects may increase with higher doses of the active ingredient.
Clinical studies of approved dapoxetine medications indicate that nausea, dizziness and headaches, in particular, may occur more frequently at a strength of 60 mg than at 30 mg.
The frequency of these side effects with Dapocare 60 mg cannot be reliably assessed without confirmed product-specific safety data.
Dapoxetine may impair circulatory regulation. A drop in blood pressure may occur, particularly when standing up, and may be accompanied by light-headedness or a temporary loss of consciousness.
Alcohol consumption, dehydration and certain medications may increase the risk of additional circulatory problems.
If adverse effects occur, no further doses should be taken without consulting a healthcare professional. Individuals experiencing dizziness, light-headedness or visual disturbances must not drive or operate machinery.
The side effects described above are based on the known safety profile of approved dapoxetine-containing medications. They do not replace confirmed prescribing information or a patient information leaflet for Dapocare 60 mg.
Due to the stated strength of dapoxetine in Dapocare 60 mg, particular safety considerations must be taken into account. The active ingredient may affect the nervous system and circulatory regulation, as well as interact with other medications.
For approved dapoxetine medications, 60 mg represents the maximum recommended single dose. This strength is not intended as a starting dose. The risk of adverse effects may increase with higher doses.
Dapoxetine may cause a drop in blood pressure when standing up (orthostatic hypotension) and temporary loss of consciousness.
Particular health risks are associated with:
Careful medical assessment is required in individuals with current or previous mental health conditions. Dapoxetine is not intended for the treatment of depression.
Immediate medical attention is required in the event of seizures, significant mood changes or suicidal thoughts.
Alcohol should be avoided when taking dapoxetine, as it may increase light-headedness and circulatory reactions. This may also increase the risk of falls and injuries.
Particular risks of drug interactions are associated with certain antidepressants, serotonergic medications and medications that affect the metabolism of dapoxetine.
Dapoxetine may impair alertness and reaction times. Individuals experiencing dizziness, light-headedness, difficulty concentrating or visual disturbances must not drive or operate machinery.
The pharmaceutical quality, bioequivalence and regulatory approval of Dapocare 60 mg have not been confirmed. The safety information for other dapoxetine-containing medications does not replace product-specific prescribing information.
Use without prior medical assessment should be avoided.
Dapoxetine, the active ingredient listed for Dapocare 60 mg, has various contraindications. Certain pre-existing medical conditions and medications taken concurrently may increase the risk of serious health complications.
Known contraindications for approved dapoxetine-containing medications include:
Approved dapoxetine medications for the treatment of premature ejaculation are intended for adult men aged 18 to 64 years. Adequate safety and effectiveness have not been established for other age groups.
Dapoxetine affects serotonin regulation and is metabolised by certain enzymes in the liver. Other medications may influence these processes, thereby increasing the risk of adverse effects.
The prescribing information for Priligy advises against concurrent use with PDE-5 inhibitors such as sildenafil, tadalafil or vardenafil. This combination may impair circulatory regulation and increase the risk of orthostatic hypotension.
Alcohol may intensify the neurological side effects of dapoxetine and increase the risk of loss of consciousness and injuries. Grapefruit juice may affect the metabolism of the active ingredient and lead to increased dapoxetine concentrations.
Careful medical assessment is required in individuals with kidney impairment, epilepsy, blood clotting disorders or existing mental health conditions.
The contraindications and interactions listed above are based on the prescribing information for approved dapoxetine medications. They do not constitute a complete product-specific patient information leaflet for Dapocare 60 mg.
Existing medical conditions and all medications being taken should be discussed with a doctor or pharmacist. Use without medical supervision should be avoided.
Dapoxetine, the active ingredient listed for Dapocare 60 mg, belongs to a group of medications known as selective serotonin reuptake inhibitors (SSRIs). Its pharmacological action is based on its effects on serotonergic signalling pathways in the nervous system.
Dapoxetine inhibits the reuptake of the neurotransmitter serotonin into nerve cells. This alters the availability of serotonin in the synaptic cleft and its effects on specific receptors.
Serotonin is involved, among other functions, in the regulation of the ejaculatory reflex. The effects of dapoxetine on premature ejaculation are associated with its influence on these neurological processes.
Ejaculation is a complex physiological process controlled by the central and peripheral nervous systems. Various neurotransmitters and receptors influence the functioning of this reflex.
The precise relationship between serotonergic signalling pathways and individual control over ejaculation is not fully understood.
Dapoxetine differs fundamentally from active ingredients such as sildenafil, tadalafil and vardenafil:
Dapoxetine is not intended for the treatment of erectile dysfunction and does not directly increase libido.
The effectiveness and safety of dapoxetine in the treatment of diagnosed premature ejaculation have been investigated in randomised, placebo-controlled clinical studies.
These studies evaluated several aspects, including ejaculation latency time, perceived control over ejaculation and the psychological distress associated with the condition.
The observed treatment effects must be weighed against potential adverse effects. Nausea, dizziness and circulatory problems, in particular, should be considered when assessing the medical benefits and risks.
The pharmacological properties of dapoxetine differ from those of many other selective serotonin reuptake inhibitors. Individual metabolism, existing medical conditions and medications taken concurrently may influence its effects.
No confirmed product-specific studies are available for Dapocare 60 mg that would allow its onset of action, duration of action, bioequivalence and clinical effectiveness to be reliably assessed.
Premature ejaculation may have various physical and psychological causes. Appropriate treatment requires an individual medical assessment. The following advice is intended to support general sexual health and medication safety.
A urological or sexual health assessment is recommended for recurring symptoms. This may take into account potential underlying medical conditions, psychological stress and other sexual dysfunctions.
In addition to medication, sexual therapy and behavioural therapy approaches may be appropriate depending on the underlying cause. Open communication within the relationship may help reduce performance pressure and psychological distress.
Inform your doctor about all medications you take regularly or occasionally. These include, in particular, antidepressants, blood pressure-lowering medications, herbal preparations and dietary supplements.
Existing medication treatments must not be changed or discontinued without medical supervision.
Alcohol may intensify the adverse effects of dapoxetine and increase the risk of dizziness, loss of consciousness and injuries. Dehydration may also contribute to circulatory problems.
Immediate medical attention is required in the event of loss of consciousness, seizures or severe circulatory problems.
Traceable origin, complete manufacturer documentation and verifiable regulatory approval are important requirements for medication safety. The fact that the stated active ingredient is the same as that of an approved medication does not, by itself, establish pharmaceutical equivalence.
The official prescribing information, pharmaceutical quality and regulatory approval status of Dapocare 60 mg have not been confirmed. Use without prior medical assessment should be avoided.
Dapocare 60 mg is described as a dapoxetine-containing medication. According to its labelling, each film-coated tablet contains 60 mg of dapoxetine in the form of dapoxetine hydrochloride. The actual composition and pharmaceutical quality must be independently confirmed.
Dapoxetine belongs to a group of medications known as selective serotonin reuptake inhibitors (SSRIs). The active ingredient affects serotonergic signalling pathways in the nervous system involved in the regulation of ejaculation.
According to their labelling, both medications contain the same active ingredient at the same strength. However, pharmaceutical equivalence or bioequivalence between Dapocare and Priligy has not been confirmed.
For approved dapoxetine medications, 60 mg represents the maximum recommended single dose. This strength is not intended as a starting dose and may be associated with an increased risk of side effects.
No. Dapoxetine differs pharmacologically from sildenafil, tadalafil and vardenafil. It is used in approved medications to treat diagnosed premature ejaculation.
Known side effects of dapoxetine include nausea, headaches, dizziness, diarrhoea and sleep disturbances. More serious risks include drops in blood pressure and fainting episodes.
The prescribing information for Priligy advises against concurrent use with PDE-5 inhibitors such as sildenafil or tadalafil. This combination may impair circulatory regulation and increase the risk of a drop in blood pressure.
Alcohol may intensify adverse effects such as light-headedness and dizziness. It may also increase the risk of loss of consciousness and associated injuries. This combination should be avoided.
The regulatory approval status of Dapocare 60 mg in Germany has not been confirmed. Dapoxetine is a prescription-only active ingredient. The approval of Priligy does not automatically mean that Dapocare is also approved.
Immediate medical attention is required in the event of loss of consciousness, seizures, severe allergic reactions, pronounced circulatory problems or signs of serotonin syndrome.
We provide only general information about medications which does not cover all directions, possible remedy integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.
Тerms and conditions